China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has announced a licensing, supply, and distribution agreement with US medical device firm Eyedetec Medical Inc. The agreement grants Zhaoke regulatory filing, import, promotion, distribution, sales, and marketing rights to Eyedetec’s dry eye device, Eye Lipid Mobilizer (ELM). The deal covers a broad territory including Greater China, South Korea, and ASEAN countries, with no financial details disclosed.
ELM: A Revolutionary Approach to Dry Eye Syndrome Treatment
The Eye Lipid Mobilizer (ELM) is a device designed to treat moderate-to-severe dry eye syndrome by stabilizing the lipid layer of the eye tear film. Its therapeutic effect lies in reducing tear evaporation and promoting eye surface health. ELM uniquely combines multiple mechanisms to transfer heat to the eyelid, reducing the viscosity of lipids in the Meibomian gland. A new form of resonant frequency stimulation is then used to vibrate within a certain frequency range, inducing the liquefaction and flow of lipids in the Meibomian gland, followed by shearing thinning. Finally, neuromodulation activates the lacrimal gland functional units, inducing the discharge of eyelid fat from the Meibomian gland.
ELM’s Market Potential and US Filing Preparations
As ELM is being prepared for market filing in the US, it is expected to become a prescribed, household therapeutic solution for dry eye syndrome by addressing the root cause of the condition. This partnership with Lee’s Pharmaceutical Holdings Ltd and its subsidiary Zhaoke Ophthalmology Ltd is set to bring this innovative treatment to a broader patient population across Asia, potentially transforming the management of dry eye syndrome in the region.-Fineline Info & Tech
